MET and prostate cancer: Reversed the doxorubicin resistance of prostate cancer cells by inhibiting c-met expression in PC3/R cells.promoted the doxorubicin-induced apoptosis in PC3/R cells through the mitochondrial/reaction oxygen species pathway.